Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ginkgolide J is a terpene lactone and a minor constituent of the terpene trilactone mixture found in Ginkgo biloba leaves. It belongs to the class of organic compounds known as ginkgolides and bilobalides, which are diterpene lactones. Ginkgolide J exhibits neuroprotective and antioxidative activities, including prevention of amyloid-β-induced cell death in cellular models of Alzheimer’s disease and inhibition of superoxide and hydroperoxyl radical formation. Mechanistically, it acts as an inhibitor of glycine receptor (GlyR)-operated channels with an IC50 around 2 μM. It also demonstrates anti-inflammatory effects by inhibiting MAPK (mitogen-activated protein kinase) pathways, toll-like receptor signaling (TLR), arachidonic acid inflammatory pathway components such as IL-5 and IL-13, TNF receptor-mediated apoptosis, and functions as a free radical scavenger[1][3][4][5][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ginkgolide J.